HALOZYME THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
HALOZYME THERAPEUTICS, INC. (HALO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $17.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $17.94M, a 47.54% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $17.00M, a 59.25% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $16.57M, a 44.57% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $12.16M, a 3.32% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $51.56M, a 18.85% increase from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $43.38M, a 18.47% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $36.62M, a 50.10% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $24.40M, a 17.18% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $17.94M 10-Q · filed 2026-08-06 | $34.94M 10-Q · filed 2026-08-06 | $51.51M derived: sum of 3 quarters · filed 2026-08-06 | $63.67M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $17.00M 10-Q · filed 2026-05-11 | $33.57M derived: sum of 2 quarters · filed 2026-05-11 | $45.73M derived: sum of 3 quarters · filed 2026-05-11 | $57.89M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $28.73M derived: sum of 2 quarters · filed 2026-02-17 | $40.89M derived: sum of 3 quarters · filed 2026-08-06 | $51.56M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $12.16M 10-Q · filed 2025-11-03 | $24.32M derived: sum of 2 quarters · filed 2026-08-06 | $34.99M 10-Q · filed 2025-11-03 | $46.46M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $12.16M 10-Q · filed 2026-08-06 | $22.83M 10-Q · filed 2026-08-06 | $34.30M derived: sum of 3 quarters · filed 2026-08-06 | $46.87M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $10.67M 10-Q · filed 2026-05-11 | $22.14M derived: sum of 2 quarters · filed 2026-05-11 | $34.71M derived: sum of 3 quarters · filed 2026-05-11 | $44.18M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $11.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $24.04M derived: sum of 2 quarters · filed 2026-02-17 | $33.51M derived: sum of 3 quarters · filed 2026-02-17 | $43.38M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $12.58M 10-Q · filed 2025-11-03 | $22.05M derived: sum of 2 quarters · filed 2025-11-03 | $31.92M 10-Q · filed 2025-11-03 | $41.59M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-06-30 | $9.47M 10-Q · filed 2025-08-05 | $19.34M 10-Q · filed 2025-08-05 | $29.01M derived: sum of 3 quarters · filed 2026-02-17 | $38.38M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-03-31 | $9.87M 10-Q · filed 2025-05-06 | $19.54M derived: sum of 2 quarters · filed 2026-02-17 | $28.91M derived: sum of 3 quarters · filed 2026-02-17 | $38.53M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2023-12-31 | $9.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $19.03M derived: sum of 2 quarters · filed 2026-02-17 | $28.65M derived: sum of 3 quarters · filed 2026-02-17 | $36.62M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $9.37M 10-Q · filed 2024-10-31 | $18.99M derived: sum of 2 quarters · filed 2024-10-31 | $26.96M 10-Q · filed 2024-10-31 | $34.18M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2023-06-30 | $9.62M 10-Q · filed 2024-08-06 | $17.59M 10-Q · filed 2024-08-06 | $24.81M derived: sum of 3 quarters · filed 2025-02-18 | $31.61M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2023-03-31 | $7.97M 10-Q · filed 2024-05-07 | $15.19M derived: sum of 2 quarters · filed 2025-02-18 | $21.99M derived: sum of 3 quarters · filed 2025-02-18 | $27.62M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2022-12-31 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $14.02M derived: sum of 2 quarters · filed 2025-02-18 | $19.66M derived: sum of 3 quarters · filed 2025-02-18 | $24.40M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $6.80M 10-Q · filed 2023-11-06 | $12.43M derived: sum of 2 quarters · filed 2023-11-06 | $17.17M 10-Q · filed 2023-11-06 | $22.30M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-06-30 | $5.63M 10-Q · filed 2023-08-08 | $10.38M 10-Q · filed 2023-08-08 | $15.50M derived: sum of 3 quarters · filed 2024-02-20 | $20.90M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-03-31 | $4.74M 10-Q · filed 2023-05-09 | $9.87M derived: sum of 2 quarters · filed 2024-02-20 | $15.27M derived: sum of 3 quarters · filed 2024-02-20 | $20.64M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2021-12-31 | $5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $10.53M derived: sum of 2 quarters · filed 2024-02-20 | $15.90M derived: sum of 3 quarters · filed 2024-02-20 | $20.82M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $5.40M 10-Q · filed 2022-11-08 | $10.77M derived: sum of 2 quarters · filed 2022-11-08 | $15.69M 10-Q · filed 2022-11-08 | $19.89M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | $5.37M 10-Q · filed 2022-08-09 | $10.29M 10-Q · filed 2022-08-09 | $14.49M derived: sum of 3 quarters · filed 2023-02-21 | $18.71M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-03-31 | $4.92M 10-Q · filed 2022-05-10 | $9.12M derived: sum of 2 quarters · filed 2023-02-21 | $13.34M derived: sum of 3 quarters · filed 2023-02-21 | $17.60M derived: sum of 4 quarters · filed 2023-02-21 | |
| 2020-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $8.42M derived: sum of 2 quarters · filed 2023-02-21 | $12.67M derived: sum of 3 quarters · filed 2023-02-21 | $17.20M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $4.22M 10-Q · filed 2021-11-02 | $8.48M derived: sum of 2 quarters · filed 2021-11-02 | $13.01M 10-Q · filed 2021-11-02 | $20.24M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-06-30 | $4.26M 10-Q · filed 2021-08-09 | $8.79M 10-Q · filed 2021-08-09 | $16.02M derived: sum of 3 quarters · filed 2022-02-22 | $24.26M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2020-03-31 | $4.53M 10-Q · filed 2021-05-10 | $11.76M derived: sum of 2 quarters · filed 2022-02-22 | $20.00M derived: sum of 3 quarters · filed 2022-02-22 | $29.83M derived: sum of 4 quarters · filed 2022-02-22 | |
| 2019-12-31 | $7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $15.47M derived: sum of 2 quarters · filed 2022-02-22 | $25.30M derived: sum of 3 quarters · filed 2022-02-22 | $34.78M 10-K · filed 2022-02-22 | |
| 2019-09-30 | $8.24M 10-Q · filed 2020-11-02 | $18.07M derived: sum of 2 quarters · filed 2020-11-02 | $27.55M 10-Q · filed 2020-11-02 | $36.56M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-06-30 | $9.83M 10-Q · filed 2020-08-10 | $19.31M 10-Q · filed 2020-08-10 | $28.32M derived: sum of 3 quarters · filed 2021-02-23 | $37.19M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-03-31 | $9.47M 10-Q · filed 2020-05-11 | $18.49M derived: sum of 2 quarters · filed 2021-02-23 | $27.35M derived: sum of 3 quarters · filed 2021-02-23 | $36.83M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2018-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $17.88M derived: sum of 2 quarters · filed 2021-02-23 | $27.36M derived: sum of 3 quarters · filed 2021-02-23 | $35.70M 10-K · filed 2021-02-23 | |
| 2018-09-30 | $8.87M 10-Q · filed 2019-11-12 | $18.34M derived: sum of 2 quarters · filed 2019-11-12 | $26.68M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $9.48M 10-Q · filed 2019-08-06 | $17.82M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $8.34M 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $30.67M 10-K · filed 2020-02-24 | ||||
| 2016-12-31 | $25.59M 10-K · filed 2019-02-21 | ||||
| 2015-12-31 | $20.84M 10-K · filed 2018-02-20 | ||||
| 2014-12-31 | $15.27M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $9.54M 10-K · filed 2016-02-29 | $9.54M 10-K · filed 2014-02-28 | |||
| 2012-12-31 | $8.35M 10-K · filed 2015-03-02 | $8.35M 10-K · filed 2013-03-01 | |||
| 2011-12-31 | $5.57M 10-K · filed 2014-02-28 | ||||
| 2010-12-31 | $4.87M 10-K · filed 2013-03-01 | ||||
| 2009-12-31 | $4.53M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |